Immune checkpoint inhibitors in pediatric patients with melanoma: a systematic literature review
Authors:
Open Access
- 26 August 2024
- journal article
- review article
- Published by Taylor & Francis in Melanoma Management
- Vol. 11 (1) , 2382075
Abstract
Aim: This study summarized the existing evidence on the outcomes and safety of anti-PD-1s, anti-PD-L1s and anti-CTLA-4s in pediatric patients with melanoma.Keywords
Funding Information
- Bristol Myers Squibb
This publication has 38 references indexed in Scilit:
- Cutaneous melanoma in adolescents and young adultsPediatric Blood & Cancer, 2018
- Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosumBritish Journal of Dermatology, 2017
- Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanomaEuropean Journal of Cancer, 2017
- Paediatric melanomaJournal of the European Academy of Dermatology and Venereology, 2017
- Genomic analysis and clinical management of adolescent cutaneous melanomaPigment Cell & Melanoma Research, 2017
- Bone marrow metastasis of malignant melanoma in childhood arising within a congenital melanocytic nevusBiomedical Papers, 2016
- Cutaneous malignant melanoma in children and adolescents treated in pediatric oncology unitsPediatric Blood & Cancer, 2016
- Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid TumorsClinical Cancer Research, 2016
- Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Incidence of Childhood and Adolescent Melanoma in the United States: 1973–2009Pediatrics, 2013